Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
JPMorgan Chase
JPM
|
$651M |
| 2 |
Charter Communications
CHTR
|
$643M |
| 3 |
Parker-Hannifin
PH
|
$606M |
| 4 |
Goldman Sachs
GS
|
$534M |
| 5 |
FedEx
FDX
|
$376M |
Top Sells
| 1 |
Biogen
BIIB
|
$701M |
| 2 |
American Tower
AMT
|
$665M |
| 3 |
Nike
NKE
|
$595M |
| 4 |
AGN
Allergan plc
AGN
|
$569M |
| 5 |
McDonald's
MCD
|
$556M |
Sector Composition
| 1 | Technology | 18.72% |
| 2 | Consumer Discretionary | 17.48% |
| 3 | Healthcare | 13.38% |
| 4 | Communication Services | 12.13% |
| 5 | Financials | 11.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Amicus Therapeutics
FOLD
$2.51B
| $46.1M | 0.05% |
9,277,910
+1,371,434
| +17% | +$6.82M |
|
277
Curtiss-Wright
CW
$18.3B
| $45.8M | 0.05% |
465,525
-308,450
| -40% | -$30.3M |
|
278
Molina Healthcare
MOH
$9.42B
| $44.9M | 0.05% |
828,290
+68,576
| +9% | +$3.72M |
|
279
Pembina Pipeline
PBA
$22B
| $44.7M | 0.05% |
1,426,951
+105,854
| +8% | +$3.32M |
|
280
Toll Brothers
TOL
$14.3B
| $44.3M | 0.05% |
1,428,454
+797,170
| +126% | +$24.7M |
|
281
Altria Group
MO
$111B
| $43.9M | 0.05% |
649,538
+623,368
| +2,382% | +$42.2M |
|
|
BCR
282
DELISTED
CR Bard Inc.
BCR
| $43.7M | 0.05% |
+194,559
| New | +$43.7M |
|
283
W.R. Berkley
WRB
$27.4B
| $43.7M | 0.05% |
2,216,724
-189,847
| -8% | -$3.74M |
|
|
CAA
284
DELISTED
CalAtlantic Group, Inc.
CAA
| $43.6M | 0.05% |
1,282,142
-120,088
| -9% | -$4.08M |
|
285
Pebblebrook Hotel Trust
PEB
$1.39B
| $43.4M | 0.05% |
1,457,424
+31,588
| +2% | +$940K |
|
|
DGI
286
DELISTED
DigitalGlobe Inc.
DGI
| $43.1M | 0.05% |
1,504,847
+73,217
| +5% | +$2.1M |
|
287
Marathon Petroleum
MPC
$54.7B
| $42.9M | 0.05% |
851,502
-56,378
| -6% | -$2.84M |
|
288
Wendy's
WEN
$1.93B
| $42.8M | 0.05% |
3,168,245
-419,524
| -12% | -$5.67M |
|
289
Lockheed Martin
LMT
$108B
| $42.5M | 0.05% |
169,953
+30,816
| +22% | +$7.7M |
|
|
GOLD
290
DELISTED
Randgold Resources Ltd
GOLD
| $42.4M | 0.05% |
555,067
-39,950
| -7% | -$3.05M |
|
|
ALR
291
DELISTED
Alere Inc
ALR
| $42.3M | 0.05% |
1,086,380
+1,935
| +0.2% | +$75.4K |
|
|
SAGE
292
DELISTED
Sage Therapeutics
SAGE
| $42.3M | 0.05% |
828,475
+2,731
| +0.3% | +$139K |
|
293
Exelixis
EXEL
$10.1B
| $41.8M | 0.05% |
2,805,314
+2,305,314
| +461% | +$34.4M |
|
|
AGN.PRA
294
DELISTED
Allergan plc.
AGN.PRA
| $41.8M | 0.05% |
54,846
+153
| +0.3% | +$117K |
|
295
Rio Tinto
RIO
$103B
| $41.1M | 0.05% |
1,068,258
-85,110
| -7% | -$3.27M |
|
|
FLIR
296
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
| $41M | 0.05% |
1,132,969
+19,447
| +2% | +$704K |
|
297
West Pharmaceutical
WST
$18.3B
| $40.7M | 0.05% |
+480,136
| New | +$40.7M |
|
|
298
Biogen
BIIB
$20.4B
| $40.3M | 0.05% |
142,286
-2,472,097
| -95% | -$701M |
|
|
ADSW
299
DELISTED
Advanced Disposal Services, Inc.
ADSW
| $40.3M | 0.05% |
+1,812,204
| New | +$40.3M |
|
300
Travere Therapeutics
TVTX
$1.89B
| $40.2M | 0.04% |
2,125,894
+2,407
| +0.1% | +$45.6K |
|